BTIG lowered the firm’s price target on Liquidia (LQDA) to $40 from $45 and keeps a Buy rating on the shares after having attended the United Therapeutics (UTHR) versus Liquidia ‘327 Hatch Waxman trial in Delaware this week. The firm still sees “favorable odds” of Liquidia prevailing past United’s ‘327 patent, but lowers its view of the probability of success of Yutrepia in pulmonary hypertension associated with interstitial lung disease to 85% from 99% to “more appropriately reflect this unresolved risk,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies put volume heavy and directionally bearish
- Liquidia Secures $50 Million Funding Boost
- Liquidia Technologies Signs Lease for New Facility
- Liquidia Technologies Holds Annual Stockholders Meeting
- Buy Rating for Liquidia Technologies Driven by Promising YUTREPIA Launch and Favorable Competitive and Legal Landscape